Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms

Summary

The primary objective of this study is to evaluate the long-term safety and tolerability of orally administered telotristat etiprate.

Timeline

Start

2014-01-14

Primary completion

2018-09-12

Completion

2018-09-12

Publications

• Horsch D, Anthony L, Gross DJ, Valle JW, Welin S, Benavent M, Caplin M, Pavel M, Bergsland E, Oberg K, Kassler-Taub KB, Binder P, Banks P, Lapuerta P, Kulke MH. Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study. Neuroendocrinology. 2022;112(3):298-310. doi: 10.1159/000516958. Epub 2021 May 3.

Drugs

Indications